July 22, 2022
8:00 am  -  4:00 pm

Origins of Cancer: Honoring Dr. George Vande Woude, an Oncogene Pioneer

Van Andel Institute’s Origins of Cancer symposium brings together students, scientists and medical professionals to explore paradigm-shifting cancer research. The 2022 symposium will honor the late Dr. George Vande Woude, the Institute’s founding research director and a groundbreaking scientist whose discovery of the MET oncogene revolutionized our understanding of cancer. This year’s distinguished roster of speakers will highlight Dr. Vande Woude’s legacy and recent breakthroughs in the oncogene field.

To be added to our email list or for questions, please contact Courtney Zirkle at Courtney.Zirkle@vai.org.

July 22, 2022

9:00 am
9:00 am  - 9:15 am

Opening Remarks and Video

9:25 am  - 11:10 am

Session One

Tony Hunter Ph.D.
Harold Varmus, M.D.
11:10 am  - 10:00 am

Break

11:25 am  - 12:35 pm

Session Two

Luis F. Parada, Ph.D.
12:35 pm  - 1:55 pm

Lunch and Poster Session

1:55 pm  - 3:40 pm

Session Three

Frank McCormick, Ph.D., FRS, D.Sc. (hon)
Morag Park, Ph.D., C.Q., FRSC, FCAHS
3:40 pm  - 3:55 pm

Break

3:55 pm  - 4:55 pm

Session Four

Sue VandeWoude, DVM, DACLAM
4:55 pm  - 5:00 pm

Closing Remarks

Brandon Oswald, Van Andel Institute Graduate School

Professor
Renato Dulbecco Chair in Cancer Research
Salk Institute for Biological Studies

Tony Hunter received his B.A. and Ph.D. from the University of Cambridge, England, and completed postdoctoral training at the Salk Institute for Biological Studies and the University of Cambridge. He joined the faculty of the Salk Institute in 1975, where he is currently Professor and Renato Dulbecco Chair in Cancer Research. In 1979, through his work on tumor viruses, he discovered a new class of protein kinases that phosphorylate tyrosine residues in proteins, establishing that dysregulated tyrosine phosphorylation by an activated tyrosine kinase can cause cancer. He and others went on to show that tyrosine phosphorylation is a widespread reversible protein modification essential for the regulation of a wide variety of cellular processes in multicellular eukaryotes, including transmembrane signal transduction by surface receptors. His work led to the realization that aberrant tyrosine phosphorylation is causal in several types of human cancer and in other diseases, and this has led to the successful development of small molecule inhibitors that target disease-causing tyrosine kinases, known as TKIs, such as Gleevec, a BCR-ABL inhibitor used for treatment of chronic myelogenous leukemia. As of January 2022, over 60 TKIs have been approved for clinical use world wide. Hunter has received many awards for his work on tyrosine phosphorylation, and has been elected to several academic societies, including the U.S. National Academy of Sciences and the Royal Society of London.

Professor, UCSF Helen Diller Family Comprehensive Cancer Center
David A. Wood Distinguished Professor of Tumor Biology and Cancer Research
Scientific Director, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD

Frank McCormick, PhD, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. In addition, Dr. McCormick’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Dr. McCormick’s current research interests center on ways of targeting Ras proteins and their regulators, including the NF1 protein neurofibromin.

Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. He is the author of over 350 scientific publications and holds more than 20 issued patents. Dr. McCormick was Director of the Helen Diller Family Comprehensive Cancer Center from 1997 to 2014. He also served as President, 2012-2013, for the American Association for Cancer Research. Since 2013, Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.

Dr. McCormick is a Fellow of the Royal Society and a member of the National Academy of Sciences.

Director, Brain Tumor Center
Albert C. Foster Chair
American Cancer Society Research Professor
Memorial Sloan Kettering Cancer Center

Luis F. Parada obtained a B.S. from the University of Wisconsin and a Ph.D. in Biology from MIT, identifying oncogenes in human cancer. He was a Damon Runyon and Helen Hay Whitney Postdoctoral Fellow at the Pasteur Institute. He headed the Molecular Embryology Section at the National Cancer Institute in Frederick, MD from 1988 to 1994 when he moved to the University of Texas Southwestern Medical Center at Dallas as the inaugurating Diana and Richard C. Strauss Distinguished Chair in Developmental Biology, and was Director of the Kent Waldrep Foundation Center for Basic Neuroscience Research. During his time in Dallas, Dr. Parada advanced his studies of nerve cell survival and regeneration, mood disorders, and renewed his attention on cancer with emphasis on the nervous system. His laboratory uses genetic mouse models to study human disease including Neurofibromatosis, cancers of the nervous system, autism, and neural development. In 2015 Dr. Parada moved his laboratory to Memorial Sloan Kettering Cancer Center to assume leadership of the interdisciplinary Brain Tumor Center. In addition Dr. Parada holds the Albert C. Foster Chair and is Professor of Cancer Biology and Genetics. In recognition of his contributions to science, Dr. Parada has been elected to: The National Academy of Sciences; The American Academy of Arts and Sciences: The Institute of Medicine – National Academy of Sciences (National Academy of Medicine); The American Association for the Advancement of Science (AAAS), The Academy of Medicine, Engineering and Science of Texas TAMEST); and is a life-time American Cancer Society Professor.

Professor, Departments of Oncology and Biochemistry
McGill University

Dr. Morag Park is a Professor in the Departments of Oncology and Biochemistry and joined McGill in 1989. She is a Knight of the Ordre national du Québec, Fellow of the Royal Society of Canada, Fellow of the Canadian Academy of Health Sciences, James McGill Professor and holds the Diane and Sal Guerrera Chair in Cancer Genetics at McGill University. Dr. Park received a B.Sc. with first class honors from the University of Glasgow, a Ph.D. in Viral carcinogenesis at the Medical Research Council Virology Institute in Scotland and completed postdoctoral training at the National Institutes for Cancer Research in Washington DC, US. She joined McGill University in 1989. She was the Director of the Molecular Oncology Group at the McGill University Health Centre (2006-8), Scientific Director of the Institute of Cancer Research for the CIHR (2008-13), co-chair of the Canadian Cancer Research Alliance (2008-2010) and is now Director of the Goodman Cancer Institute (2013-present). She is a recipient of a Canadian Cancer Research Alliance Award (2015) for Exceptional Leadership in Cancer Research, and also a recipient of the Canadian Society for Molecular Biosciences Arthur Wynne Gold Medal Prize (2016) for having made major contributions to biochemistry, molecular and cell biology in Canada. Most recently she is a recipient of the Canadian Cancer Society Robert L. Noble Prize (2017), the Quebec Breast Cancer Foundation Grand Prix Scientifique (2019), and the Club de Recherches Cliniques du Québec Michel Sarrazin Award (2021).

Dr. Park is a research leader in the field of receptor tyrosine kinases (RTK) and mechanisms of oncogenic activation of RTKs in human cancers. She cloned the Met RTK, which is now a key therapeutic target in oncology. She established the Breast Cancer Functional Genomics Group at McGill. She has pioneered studies of the breast tumour and immune microenvironment in triple negative breast cancer (TNBC).  She has established animal models as well as patient derived xenografts to study heterogeneity, tumor progression and drug response in TNBC. She was the elected chair of the Tumour Microenvironment Network of the American Association for Cancer Research (2015-2017). She has more than 230 publications, and an h-index of 81.

University Distinguished Professor, Colorado State University
Director, CSU One Health Institute

Sue VandeWoude is a veterinary virologist recognized for her studies of the biology, pathogenesis, and ecology of viral infections in felids. Her work has included virus discovery, viral co-infection interference, and cross species transmission of infections between domestic and nondomestic cats. Her disease ecology studies have indicated that anthropogenic change influences disease incidence in free-ranging bobcats and pumas, and that spillover of diseases from domestic cats to pumas occurs frequently with a range of clinical outcomes.  Her work on Feline Leukemia Virus has examined interaction between endogenous and exogenous genomes in natural and experimental infections, and has shown how these interactions modify viral replication and disease expression. Her recent studies of experimental SARS-CoV-2 infections in cats have revealed strong viral selection following inoculation with human-derived strains and during cat-to-cat transmission.  VandeWoude is currently University Distinguished Professor and Director of the CSU One Health Institute, and was elected to the National Academy of Sciences in 2019.

Lewis Thomas University Professor, Meyer Cancer Center, Weill Cornell Medicine
Senior Associate Member, New York Genome Center

Harold Varmus, M.D., co-recipient of the 1989 Nobel Prize in Physiology or Medicine for studies of the genetic basis of cancer, joined the Meyer Cancer Center of Weill Cornell Medicine as the Lewis Thomas University Professor of Medicine in April, 2015.   He is also a Senior Associate Member of the New York Genome Center, where he helps to develop programs in cancer genomics, and an adjunct professor at the Macaulay Honors College at the City University of New York.   Previously, Dr. Varmus was the Director of the National Cancer Institute for five years, the President of Memorial Sloan-Kettering Cancer Center for ten years, and Director of the National Institutes of Health for six years.   A graduate of Amherst College and Harvard University in English literature and of Columbia University in medicine, he was further trained at Columbia University Medical Center, the National Institutes of Health, and the University of California San Francisco (UCSF), before becoming a member of the UCSF basic science faculty for over two decades. He is a member of the U.S. National Academies of Sciences and Medicine, is involved in several initiatives to promote science and health in developing countries, and serves on advisory groups for several academic, governmental, philanthropic, and commercial institutions.  These positions currently include co-chair of the Mayor’s LifeSciNYC  initiative and member of advisory boards for Chan-Zuckerberg Science, the Broad and the Crick Institutes, the global health program at the Bill and Melinda Gates Foundation, three biotechnology companies (Surrozen, Dragonfly, and Volastra), and, most recently, the chair of the World Health Organization’s new Science Council.    The author of about 400 scientific papers and five books, including a 2009 memoir entitled The Art and Politics of Science, Varmus was a co-chair of President Obama’s Council of Advisors on Science and Technology, a co-founder and Chairman of the Board of the Public Library of Science, and chair of the Scientific Board of the Gates Foundation Grand Challenges in Global Health.

When is Origins of Cancer? How much does it cost?
Origins of Cancer will take place on Friday, July 22, 2022. Registration will open April 6, 2022.

The registration fee for students and postdoctoral fellows is $25. The registration fee for non-students is $50.

Will late registrations be accepted?
Unfortunately, late registrations will not be accepted. All attendees must register online by 11:59 p.m. EST Wednesday, July 13, 2022.

Can I register a group?
Yes! The registration form allows one person to register and pay for a group. Once registration is complete for one person, please click “add person” in the bottom right corner of the form. Input the second person’s information and continue in this manner until all parties in the group are registered. The system will then charge a total cost for the group.

What if I need accommodations?
Please contact Courtney Zirkle to discuss any accommodation needs.

How do I become a sponsor?
Please contact Courtney Zirkle for more information on sponsorship opportunities.

What is the refund policy?
Refund requests must be made in writing by Wednesday, July 13, 2022. After July 13, refund requests will not be honored. If you cannot attend, a substitute may attend in your place. The name and email address of the replacement attendee must be emailed to Courtney Zirkle prior to July 13, 2022. If you do not attend the program and do not submit a written refund request, Origins of Cancer will retain all registration fees. Email all cancellation requests/substitutions/ registration questions to Courtney Zirkle; requests will be addressed within three business days. In the event Origins of Cancer is canceled, full refunds will be given to all registrants.

Code of Conduct Guidelines
We are dedicated to providing a harassment-free symposium experience for all participants, regardless of gender, gender identity and expression, age, sexual orientation, disability, physical appearance, body size, race, ethnicity, religion (or lack thereof), or technology choices. We do not tolerate harassment of conference participants in any form. Sexual language and imagery is not appropriate for any conference venue, including talks, workshops, networking sessions, poster sessions, social networking platforms and other online media. Symposium participants violating these guidelines may be expelled from the symposium at the discretion of the conference organizers.

Anyone who has experienced the above, or who has witnessed such behavior, should notify Courtney Zirkle at courtney.zirkle@vai.org or Dr. Mary Winn at mary.winn@vai.org. Anonymous reporting may also be done through the EthicsPoint Hotline here.

Abstract submission will open with registration on April 6, 2022; the deadline to submit an abstract for talk consideration (graduate students and postdoctoral fellows only) is June 1, 2022. The deadline for all other poster abstracts is the last day of registration, Wednesday, July 13, 2022.

For questions or to be added to our email list, please contact Courtney Zirkle.

Eligibility
Graduate students, postdoctoral fellows, faculty and research staff are welcome to submit a poster abstract. Only graduate students and postdoctoral fellows are eligible for abstract selected talk consideration.

Abstract selected talks (students and postdoctoral fellows only)
There will be three abstract selected talks. These talks are limited to graduate students and postdoctoral fellows. Each abstract selected talk will be 15 minutes (10-minute talk + 5 minutes Q&A). Graduate students and postdoctoral fellows who wish to be considered are asked to please submit their abstract during the registration process by the June 1 deadline.

The three individuals chosen to give an abstract selected talk will  be notified on or before June 6, 2022. The selected individuals will receive a one-night paid hotel stay in Grand Rapids at the Amway Grand Plaza Hotel on July 21, the opportunity to have dinner with the speakers and organizers, as well as up to $50 reimbursement for travel expenses.

Abstract format
Submitted abstracts should represent original research. The title should be brief and descriptive, and the body should include rationale, methods and results. Please prepare abstracts using the template below.

Abstract submission
Poster abstracts should be submitted during the registration process.

Questions?
Questions regarding abstract submission, posters, or the poster session can be directed to Beth Resau.


TITLE OF ABSTRACT IN ALL CAPS (STYLE = TITLE)

Presenting Author1,2, Other Author1, and Last Author1,3(Style = Authors)

1First Dept., Institution, City, State, Country, 2Second Dept., Institution, City, State, Country, and 3Last Dept., Institution, City, State, Country (Style = Affiliations)

Body of abstract using 300 words or less. Define each abbreviation at first use. All fonts should be Arial, 11 pt. and text should be single-spaced. Once you have filled in this template, choose File>Save As and save your file as a Word document (.doc or .docx) with the filename lastname_abstract. (Style = Body)

EXAMPLE

THE ROLE OF A-SYNUCLEIN IN PARKINSON’S DISEASE PATHOLOGY

Jennifer Lamberts1 and Patrik Brundin1

1Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, United States

The pathological hallmark of Parkinson’s disease (PD) is protein-rich, intraneuronal inclusions known as Lewy bodies and Lewy neurites, which are composed primarily of aggregates of misfolded a-synuclein (a-syn) protein. Recent studies suggest…

Van Andel Institute’s Origins of Cancer symposium brings together students, scientists and medical professionals to explore paradigm-shifting cancer research. The 2022 symposium will honor the late Dr. George Vande Woude, the Institute’s founding research director and a groundbreaking scientist whose discovery of the MET oncogene revolutionized our understanding of cancer. This year’s distinguished roster of speakers will highlight Dr. Vande Woude’s legacy and recent breakthroughs in the oncogene field.

The symposium routinely attracts more than 200 attendees from across the Midwest.

Interested in sponsoring Origins of Cancer? Please contact Courtney Zirkle at courtney.zirkle@vai.org.

Van Andel Institute Graduate School Ph.D. candidate

Shelby is a fourth-year graduate student in the laboratory of Dr. Russell Jones at Van Andel Institute. Her research is focused on the tumor suppressor liver kinase B1 (LKB1), which when mutated, gives rise to a cancer predisposition syndrome called Peutz-Jeghers Syndrome. Specifically, she seeks to identify mechanisms of how LKB1 controls inflammation, and how inflammation regulated by LKB1 impacts tumor growth.

Van Andel Institute Graduate School Ph.D. candidate

Patrick Dischinger is third year graduate student in Matt Steensma’s lab, which focuses on the gene NF1 and the protein for which it codes, neurofibromin. Specifically, Patrick focuses on how mutations or alterations in NF1 expression contribute to aggressive breast cancer development and discovering new therapeutic options for this subset of breast cancer.

Van Andel Institute Graduate School Ph.D. candidate

Ariana is a fourth-year graduate student in the laboratory of Dr. Scott Rothbart at Van Andel Institute. Ariana works towards improving methodology in epigenetics research, specifically towards mapping interactions of histone post-translational modifications (PTMs) and histone PTM reader proteins.

Van Andel Institute Graduate School Ph.D. candidate

Brandon is a third-year graduate student in the laboratory of Dr. Russell Jones at Van Andel Institute. Brandon works on how dietary interventions modulates immune responses in the context of anti-tumor immunity.

M.D./Ph.D. candidate, Michigan State University College of Human Medicine and Van Andel Institute Graduate School

Nathan Spix received his B.S. in biochemistry from Oakland University in 2016. While there, he spent three years in the retinal physiology laboratory of Dr. Dao-Qi Zhang studying the function of retinal dopaminergic neurons. He subsequently matriculated into the Michigan State University-Van Andel Institute joint M.D.-Ph.D. program and completed two years of medical school training at the MSU College of Human Medicine before starting his thesis work with Van Andel Institute Graduate School. At the Graduate School, he works under the mentorship of Dr. Peter Laird studying the epigenetic origins of human colorectal cancer. His career goals include leading a translational oncology laboratory and maintaining an active oncology practice. When not at the lab, Nathan enjoys spending time with his family, playing the violin, and being outdoors.

In 2009, the Foundation for Advanced Cancer Studies Inc. (FACS) sponsored the first Origins of Cancer symposium to mark the sesquicentennial anniversary of Charles Darwin’s famous On the Origin of Species. In 2014, FACS generously set up an endowment to support Origins of Cancer for many years to come.

The story of Origins of Cancer begins many years before the first symposium was held at Van Andel Institute in 2009. Today’s symposium is a reincarnation of the Oncogene Meeting, an annual event dedicated to the latest oncogene research that was first hosted in 1985 at Hood College. Three years later, in 1988, Dr. George Vande Woude and Dr. Tony Hunter formed FACS to oversee the annual meeting. The meeting was held annually for almost two decades, with the last meeting being held in 2004. It is remembered not only for its impressive gathering of leading scientific minds, but also as a forum for young scientists to present their work. Many of those who gave early presentations at the meeting went on to prestigious careers in cancer research.1

To learn more about the Oncogene Meeting (and its famous illustrations), please read A not so brief history of the Oncogene Meeting and its cartoons.
1Hunter T, Simon J. 2007. A not so brief history of the Oncogene Meeting and its cartoons. Oncogene. 26:1260–1267


Previous themes and speakers

2021: The emerging frontier: Cancer neuroscience

  • Suzanne J. Baker, Ph.D. – Keynote lecture
  • Michelle Monje Deisseroth, M.D., Ph.D. – Keynote lecture
  • Rameen Beroukhim, M.D., Ph.D.
  • Douglas Hanahan, Ph.D.
  • Nada Jabado, M.D., Ph.D.
  • Daniel L. Marks, M.D., Ph.D.
  • Pilar Sánchez-Gómez, Ph.D.
  • Derek A. Wainwright, Ph.D.
  • Kathryn Becker, B.S. – Abstract-selected speaker
  • Erik Peterson, B.S., M.S. – Abstract-selected speaker

2020: Beyond the margins: Exploring the tumor macroenvironment

  • Mina Bissell, Ph.D. – Keynote lecture
  • Kevanc Birsoy, Ph.D.
  • Theresa A. Guise, M.D.
  • Susan Kaech, Ph.D.
  • Michael Karin, Ph.D.
  • Fatemeh Momen-Heravi, D.D.S., Ph.D., M.P.H., M.S.
  • Sheila A. Stewart, Ph.D.
  • Jennifer E. Klomp, M.S., Ph.D. – Abstract selected talk

2019: The evolution of cancer

  • Charles Swanton, FRS, FMedSci, FRCP, Ph.D. – Keynote lecture
  • David Wheeler, Ph.D.
  • Catherine Cottrell, Ph.D., FACMG
  • Hui Shen, Ph.D.
  • Ludmil Alexandrov, Ph.D.
  • Jean C.Y. Wang, M.D., Ph.D., FRCPC
  • Marcelo Aldaz, M.D., Ph.D.

2018: Genetic and epigenetic alterations in pediatric cancers

  • Cigall Kadoch, Ph.D.
  • Alex Kentsis, M.D., Ph.D.
  • Elizabeth R. Lawlor, M.D., Ph.D.
  • Charles Mullighan, MBBS (hons), M.Sc., M.D.
  • Elizabeth J. Perlman, M.D.
  • Joanna Phillips, M.D., Ph.D.
  • Charles W.M. Roberts, M.D., Ph.D.
  • Kimberly Stegmaier, M.D.

2017: Tackling provocative questions

  • Chetan Bettegowda, M.D., Ph.D.
  • Lisa A. Boardman, M.D.
  • Scott Bultman, Ph.D.
  • Timothy Chan, M.D., Ph.D.
  • Craig M. Crews, Ph.D.
  • Emily Greenspan, Ph.D.
  • Christine A. Iacobuzio-Donahue, M.D., Ph.D.
  • Lyse A. Norian, Ph.D.
  • Chrystal Paulos, Ph.D.

2016: Exploring tumor complexity

  • Emily Bernstein, Ph.D.
  • Rani E. George, M.D., Ph.D.
  • David Langenau, Ph.D.
  • Sophia Lunt, Ph.D.
  • Nicholas Navin, Ph.D.
  • Susan M. Rosenberg, Ph.D.
  • Dylan Taatjes, Ph.D.

2015: Beyond the genome: The role of posttranslational modifications in cancer

  • Scott Coonrod, Ph.D.
  • Michael Freitas, Ph.D.
  • Tony Hunter, Ph.D.
  • Karolin Luger, Ph.D.
  • Sonia Lobo Planey, Ph.D.
  • J. Michael Pierce, Ph.D.
  • Michael Rape, Ph.D.
  • Mauricio Reginato, Ph.D.

2014: Beyond the tumor cell

  • Raymond N. DuBois, M.D., Ph.D.
  • Chrislyn D’Souza-Schorey, Ph.D.
  • Susan E. Erdman, DVM, MPH
  • Johanna Joyce, Ph.D.
  • Patrick S. Moore, M.D., MPH
  • Drew M. Pardoll, M.D., Ph.D.
  • Andrei Seluanov, Ph.D.
  • Zena Werb, Ph.D.

2013: The hallmarks of cancer
(Based on the reviews in Cell by Drs. Hanahan and Weinberg)

  • Eric C. Holland, M.D., Ph.D.
  • Yiban Kang, Ph.D.
  • Jeffrey W. Pollard, Ph.D.
  • Tannishtha Reya, Ph.D.
  • Matthew G. Vander Heiden, M.D., Ph.D.
  • Victor E. Velculescu, Ph.D.
  • Peter K. Vogt, Ph.D.
  • Owen Witte, M.D.

2011: Oncogenic pathways; tumor suppressors; receptor tyrosine kinases; signal transduction; cell cycles

  • James D. Watson, Ph.D.
  • Natalie G. Ahn, Ph.D.
  • Sara Courtneidge, Ph.D.
  • Robert N. Eisenman, Ph.D.
  • Edward Harlow Jr., Ph.D.
  • Richard Jove, Ph.D.
  • Deborah Morrison, Ph.D.
  • Charles Sherr, M.D., Ph.D.

2010: Cytogenetics of cancer; oncogenic pathways; environmental factors; infectious agents; cancer stem cells; comparative oncology

  • Janet S. Butel, Ph.D.
  • Pelayo Correa, M.D.
  • Joe Gray, Ph.D.
  • Martin McMahon, Ph.D.
  • Stuart Orkin, M.D.
  • Elaine Ostrander, Ph.D.
  • Janet Rowley, M.D.
  • Margaret R. Spitz, M.D., MPH

2009: Genetic instability; cellular pathways; environmental factors (radiation, diet, and exercise); infectious agents; clonal transmission; non-coding RNAs; sporadic mutations

  • Leslie Bernstein, Ph.D
  • J. Silvio Gutkind, ph.D.
  • Brendan Manning, Ph.D.
  • Elizabeth Murchison, Ph.D.
  • David S. Pellman, M.D.
  • Frank Slack, Ph.D.
  • Jeffrey M .Trent, Ph.D.
  • Professor Sir Dillwyn Williams, FRCP, FRCPath, FMedSci

Event Details

Stay tuned for information on our 2022 program! To be added to our mailing list, please email Courtney Zirkle at courtney.zirkle@vai.org.

Venue: Van Andel Institute 333 Bostwick Ave. NE Grand Rapids

Contact Info:

Email: Courtney Zirkle

Thanks to our wonderful sponsors!

Scientific Sponsor

Discovery Sponsor

Supporting Sponsors

  • Dr. Peter A. Jones